| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2481 | 2017 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 928 | 2018 |
| Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma MB Schabath, EA Welsh, WJ Fulp, L Chen, JK Teer, ZJ Thompson, ... Oncogene 35 (24), 3209-3216, 2016 | 292 | 2016 |
| Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial BC Creelan, C Wang, JK Teer, EM Toloza, J Yao, S Kim, AM Landin, ... Nature medicine 27 (8), 1410-1418, 2021 | 210 | 2021 |
| Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer, including patients … DR Spigel, M McCleod, RM Jotte, L Einhorn, L Horn, DM Waterhouse, ... Journal of Thoracic Oncology 14 (9), 1628-1639, 2019 | 168 | 2019 |
| Update on immune checkpoint inhibitors in lung cancer BC Creelan Cancer Control 21 (1), 80-89, 2014 | 159 | 2014 |
| Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153 DM Waterhouse, EB Garon, J Chandler, M McCleod, M Hussein, R Jotte, ... Journal of Clinical Oncology 38 (33), 3863, 2020 | 144 | 2020 |
| 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I … DL Gibbons, LQ Chow, DW Kim, SW Kim, T Yeh, X Song, H Jiang, ... Journal of Thoracic Oncology 11 (4), S79, 2016 | 144 | 2016 |
| Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors AB Schrock, VW Zhu, WS Hsieh, R Madison, B Creelan, J Silberberg, ... Journal of Thoracic Oncology 13 (9), 1312-1323, 2018 | 126 | 2018 |
| Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases KA Ahmed, S Kim, J Arrington, AO Naghavi, TJ Dilling, BC Creelan, ... Journal of neuro-oncology 133, 331-338, 2017 | 123 | 2017 |
| Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) DR Spigel, M McLeod, MA Hussein, DM Waterhouse, L Einhorn, L Horn, ... Annals of Oncology 28, v461, 2017 | 120 | 2017 |
| Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of … S Peters, B Creelan, MD Hellmann, MA Socinski, M Reck, ... Cancer Research 77 (13_Supplement), CT082-CT082, 2017 | 118 | 2017 |
| The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management M Girotra, A Hansen, A Farooki, DJ Byun, L Min, BC Creelan, ... JNCI Cancer Spectrum 2 (3), pky021, 2018 | 114 | 2018 |
| Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non–small cell lung cancer JE Gray, A Saltos, T Tanvetyanon, EB Haura, B Creelan, SJ Antonia, ... Clinical Cancer Research 25 (22), 6623-6632, 2019 | 111 | 2019 |
| CheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand … M Socinski, B Creelan, L Horn, M Reck, L Paz-Ares, M Steins Ann Oncol 27 (suppl 6), 1-36, 2016 | 104 | 2016 |
| The NKG2A immune checkpoint—a new direction in cancer immunotherapy BC Creelan, SJ Antonia Nature Reviews Clinical Oncology 16 (5), 277-278, 2019 | 98 | 2019 |
| Indoleamine 2, 3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer BC Creelan, SJ Antonia, G Bepler, TJ Garrett, GR Simon, HH Soliman Oncoimmunology 2 (3), e23428, 2013 | 95 | 2013 |
| Sirt2 inhibition enhances metabolic fitness and effector functions of tumor-reactive T cells I Hamaidi, L Zhang, N Kim, MH Wang, C Iclozan, B Fang, M Liu, ... Cell metabolism 32 (3), 420-436. e12, 2020 | 82 | 2020 |
| NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv … M Socinski, B Creelan, L Horn, M Reck, L Paz-Ares, M Steins, E Felip, ... Annals of oncology 27, vi577, 2016 | 69 | 2016 |
| A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung … BC Creelan, TC Yeh, SW Kim, N Nogami, DW Kim, LQM Chow, S Kanda, ... British journal of cancer 124 (2), 383-390, 2021 | 64 | 2021 |
Steven EschrichMoffitt Cancer CenterVerified email at moffitt.org
